Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ripisartan SCHEMBL489673 | 0.85 | AGTR1 (0.73) | AGTR1 | |
| SCHEMBL9308944 | 0.81 | AGTR1 (0.69) | AGTR1 | |
| SCHEMBL9308977 | 0.80 | AGTR1 (0.66) | AGTR1 | |
| SCHEMBL22800020 | 0.77 | AGTR1 (0.63) | AGTR1 | |
| SCHEMBL9309816 | 0.77 | AGTR1 (0.63) | AGTR1 | |
| SCHEMBL9310003 | 0.76 | AGTR1 (0.62) | AGTR1 | |
| SCHEMBL9308892 | 0.76 | AGTR1 (0.62) | AGTR1 | |
| SCHEMBL9308916 | 0.76 | AGTR1 (0.61) | AGTR1 | |
| SCHEMBL9309944 | 0.75 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL9309293 | 0.74 | AGTR1 (0.59) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113056465-B | Tetrahydropyrane (THP) -substituted bicyclic pyrimidinedione compounds | 迈奥卡迪亚公司 | 2025-01-28 | — | — | CN | claimed |
| EP-3873904-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2024-07-10 | — | — | EP | claimed |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-10-27 | — | — | US | claimed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | claimed |
| EP-4736855-A2 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616697-B2 | Methods of treatment with myosin modulator | MyoKardia, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4464321-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MyoKardia, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250241903-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MYOKARDIA INC (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2022047004-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | SEDELMEIER GOTTFRIED | 2011-07-28 | — | — | US | disclosed |
| US-7943647-B2 | Process for the preparation of tetrazole derivatives from organo aluminium azides | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943647-B2 | Process for the preparation of tetrazole derivatives from organo aluminium azides | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | ABL1, TBCA, TBC1D5 | AGTR1 2005/4885 |
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885 |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | AGTR1 2005/4885 |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885 |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | AGTR1 2005/4885 |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885 |
| US-12616697-B2 | Methods of treatment with myosin modulator | MYH2, MYH14, MYH10 | AGTR1 528/4885 |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | FABP3, TNNI3, TNNT2 | AGTR1 173/4885 |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 8/4885 |
| US-20250241903-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | FABP3, TNNI3, TNNT2 | AGTR1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.